Related Experiment Videos
Abstract:
5 patients treated with perhexiline maleate, 200-400 mg/day for at least 6 months, exhibited evidence of hepatitis. The picture was very similar to acute alcoholic hepatitis, clinically, biologically and histologically with presence of necrosis, Mallory's hyaline, polynuclear infiltration and to a lesser degree, steatosis. Association with peripheral neuropathy, hypoglycemia, and renal failure appears strikingly frequently. The evolution was severe since 3 patients died within 6 months, even after treatment withdrawal. Further studies are to be done to understand the mechanisms of hepatic and neurologic toxicity, and to measure the hazards of this drug. These studies could bring a new insight to alcohol toxicity.
Insights
Perhexiline maleate can cause severe hepatitis, mimicking alcoholic liver injury. This drug also shows frequent associations with neuropathy, hypoglycemia, and renal failure, necessitating further research into its toxicity.
Area of Science:
- Hepatology
- Toxicology
- Pharmacology
Background:
- Perhexiline maleate is a medication used for certain cardiovascular conditions.
- Understanding drug-induced liver injury (DILI) is crucial for patient safety.
Observation:
- Five patients treated with perhexiline maleate (200-400 mg/day for ≥6 months) developed hepatitis.
- The clinical, biological, and histological features resembled acute alcoholic hepatitis.
Findings:
- Hepatitis presentation included necrosis, Mallory's hyaline, polynuclear infiltration, and steatosis.
- Concurrent peripheral neuropathy, hypoglycemia, and renal failure were frequently observed.
- Three patients died within six months, despite drug withdrawal, indicating severe outcomes.
Implications:
- Perhexiline maleate poses significant risks for hepatic and neurologic toxicity.
- Further research is needed to elucidate the mechanisms of perhexiline toxicity.
- Findings may offer insights into alcohol-induced liver toxicity mechanisms.